← All trials
NCT05764525
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2021
- Primary completion
- Nov 3, 2022
- Completion date
- Nov 22, 2022
- First posted
- Mar 10, 2023
- Last posted
- Mar 10, 2023
- Enrollment
- 285
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vivozon, Inc.Lead sponsor
- Vivozon, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.